About Ottimo Pharma
Ottimo Pharma is a Healthcare company based in Dover (United Kingdom) founded in 2020. Develoeper of bifunctional medicines for cancer treatment. Ottimo Pharma has raised $140 million across 1 funding round from investors including J P Morgan, Orbimed and Janus Henderson Investors. Its Indian entity Mopharma Digital Solutions Private Limited reported revenue of ₹5.1 Lakh. Ottimo Pharma offers products and services including PD1/VEGFR2 Dual Antibodies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Ottimo Pharma was founded in 2020 and is based in Dover, United Kingdom. Focus is placed on the biotechnology sector, where bifunctional medicines for cancer treatment are developed. Antibodies targeting PD1 and VEGFR2 are combined in these drugs to address solid tumors and various other cancers. Operations center on research and drug innovation within oncology.
- Headquarters Dover, United Kingdom
- SectorsHealthcare
- Email••••••••
- Website ottimopharma.com
- Social LinkedIn
- Legal Name Mopharma Digital Solutions Private Limited
- Date of Incorporation 28 Aug, 2012
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹5.1 Lakh
FY 2024 · +1168% YoY
- Indian entity net profit₹2.1 Lakh
FY 2024 · 40% margin
- Indian entity EBITDA₹2.6 Lakh
FY 2024 · 51% margin
- Total Equity Funding$140M (USD)
in 1 rounds
- Latest Funding Round$140M (USD), Series A
Dec 2024
- InvestorsJ P Morgan
& 8 more
Associated legal entities of Ottimo Pharma
Ottimo Pharma operates through Mopharma Digital Solutions Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mopharma Digital Solutions Private Limited CIN U72900MH2012PTC235033 | Active | 28 Aug 2012 | Mumbai, Maharashtra | ₹0.1 Cr | 2 | View details |
Products & Services of Ottimo Pharma
Ottimo Pharma offers a comprehensive portfolio of products and services, including PD1/VEGFR2 Dual Antibodies.
Innovative antibodies targeting PD1 and VEGFR2 pathways for cancer treatment.
Funding Insights of Ottimo Pharma
Ottimo Pharma has successfully raised a total of $140M through 1 strategic funding round. The most recent funding activity was a Series A round of $140 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $140M
- Total Rounds 1
- Last Round Series A — $140M
- First Round $140M
(Dec 2024)
- Investors Count 9
All 1 funding rounds of Ottimo Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $140M | Series A | – | Orbimed, Avoro Capital Advisors |
9 investors in total: 9 institutional.
Investors in Ottimo Pharma
Ottimo Pharma has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital fund focused on biotechnology startups | avorocapital.com | New York, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States |
Investor details for Ottimo Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Mopharma Digital Solutions Private Limited (Ottimo Pharma)
Mopharma Digital Solutions Private Limited is the primary company behind Ottimo Pharma. The board of Mopharma Digital Solutions Private Limited currently have 2 directors; the longest-serving is Uma Ramchandra Shirodkar, appointed in 2012. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Uma Ramchandra Shirodkar DIN 05314216 | Director | 28 Aug 2012 | 14 yrs 2 mo | Mopharma Digital Solutions Private Limited |
| Ujjawala Kashinath Ghume DIN 09521559 | Additional Director | 26 Feb 2022 | 4 yrs 8 mo | Mopharma Digital Solutions Private Limited |
People of Ottimo Pharma
5 people are tracked at Ottimo Pharma (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Katherine Bell-McGuinn | Senior Vice President Clinical Development | Leadership |
David Epstein | Chief Executive Officer | Leadership |
Spencer Fisk | Chief Technical And Quality Officer | Leadership |
Dannielle Hall | Director Clinical Operations | Leadership |
Ling Zeng | GC & EVP Execution | Team |
Complete people profiles for Ottimo Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Ottimo Pharma
Figures of Mopharma Digital Solutions Private Limited, the primary company behind Ottimo Pharma, for FY 2024. Revenue was ₹5.1 Lakh (+1168% year on year). Net profit was ₹2.1 Lakh (40% margin). EBITDA was ₹2.6 Lakh (51% margin). Revenue has grown at a compounded annual rate of -3% over three years and -6% over five years.
- ₹5.1 LakhRevenue · FY 2024 · +1168% YoY
- ₹2.1 LakhNet profit · 40% margin
- ₹2.6 LakhEBITDA · 51% margin
- ₹1 LakhPaid-up capital
- -3%Revenue CAGR, 3 years
- -6%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Mopharma Digital Solutions Private Limited are on its company page.
Detailed financial statements for Ottimo Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ottimo Pharma
2 dated milestones of Ottimo Pharma across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Ottimo Pharma is founded.
- Funding First funding round of $140.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ottimo Pharma
Complete news archive for Ottimo Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ottimo Pharma
Ottimo Pharma was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Ottimo Pharma is headquartered in Dover, United Kingdom.
Ottimo Pharma is a funded company, having raised a total of $140M across 1 funding round to date. The company's 1st funding round was a Series A of $140M, raised on Dec 2024.
The primary company behind Ottimo Pharma, Mopharma Digital Solutions Private Limited, reported revenue of ₹5.1 Lakh for FY 2024, up 1168% year on year.
Ottimo Pharma was founded in 2020 and is based in Dover, United Kingdom. Focus is placed on the biotechnology sector, where bifunctional medicines for cancer treatment are developed. Antibodies targeting PD1 and VEGFR2 are combined in these drugs to address solid tumors and various other cancers. Operations center on research and drug innovation within oncology.
Ottimo Pharma offers PD1/VEGFR2 Dual Antibodies.
Ottimo Pharma has 9 investors. Key investors include J P Morgan, Orbimed, Janus Henderson Investors, RTW Investments, and Avoro Capital Advisors.
Ottimo Pharma operates through Mopharma Digital Solutions Private Limited.
The legal entities of Ottimo Pharma currently have 2 directors, including Ujjawala Kashinath Ghume, Uma Ramchandra Shirodkar.